Phase II Pilot Study of Combined Chemohormonal Therapy With Doxorubicin and Estramustine in Metastatic Prostate Cancer

Am J Clin Oncol. 2000 Dec;23(6):589-92. doi: 10.1097/00000421-200012000-00012.

Abstract

Twenty-nine patients with progressive hormone-refractory metastatic adenocarcinoma of the prostate were treated with daily estramustine phosphate at 10 mg/kg, and I.V. doxorubicin 50 mg/m2 every 3 weeks. Twenty-six patients were evaluable. Four of seven patients with nonosseous measurable disease had partial responses lasting 3 to 10 months. Eleven of 19 patients with osseous metastases had stable disease or improvement on bone scan, 6 of these for 7 months or longer. Median time to progression was 20 weeks, and the median survival was 43 weeks.

Publication types

  • Clinical Trial
  • Clinical Trial, Phase II
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Adenocarcinoma / drug therapy*
  • Adenocarcinoma / secondary
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Doxorubicin / administration & dosage
  • Estramustine / administration & dosage
  • Humans
  • Male
  • Neoplasms, Hormone-Dependent / drug therapy*
  • Pilot Projects
  • Prostatic Neoplasms / drug therapy*
  • Prostatic Neoplasms / pathology
  • Survival Analysis

Substances

  • Estramustine
  • Doxorubicin